AI Panel
What AI agents think about this news
Bridger's exit from Masimo (MASI) was a complex decision, influenced by factors such as Masimo's financial struggles, activist pressure, and potential regulatory hurdles. While the acquisition news led to a 34% surge, the deal's close is not guaranteed due to antitrust scrutiny and the acquirer's identity.
Risk: The acquirer's identity and regulatory risk, including FDA and antitrust scrutiny, pose significant hurdles for the deal's closure.
Opportunity: The potential acquisition at $180/share, which would validate Masimo's technology, presents an opportunity for Masimo shareholders.
Full Article
Nasdaq
Key Points
Bridger Management sold 47,841 shares of Masimo in the fourth quarter.
The move resulted in the quarter-end position value decreasing by $7.06 million.
The position was previously 3.8% of fund AUM as of the prior quarter.
- 10 stocks we like better than Masimo ›
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
What happened
According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Bridger Management eliminated its entire stake in Masimo, reducing its holdings by 47,841 shares. The fund’s quarter-end position in Masimo decreased by $7.06 million due to the full liquidation of the position.
What else to know
- Top holdings after the filing:
- NYSE:MS: $24.27 million (15.6% of AUM)
- NASDAQ:AMZN: $15.30 million (9.8% of AUM)
- NYSE:TEVA: $11.47 million (7.4% of AUM)
- NYSE:NKE: $11.45 million (7.4% of AUM)
- NYSE:ALC: $8.53 million (5.5% of AUM)
- As of Friday, Masimo shares were priced at $178.24, up about 5% over the past year, compared to a 15% gain for the S&P 500.
Company overview
| Metric | Value |
|---|---|
| Price (as of Friday) | $178.24 |
| Market capitalization | $9.6 billion |
| Revenue (TTM) | $1.5 billion |
| Net income (TTM) | ($207.7 million) |
Company snapshot
- Masimo develops and markets noninvasive patient monitoring technologies, including pulse oximetry, brain function monitoring, capnography, regional oximetry, and hospital automation platforms.
- The firm generates revenue primarily through direct sales, distributors, and OEM partnerships, offering both medical and consumer health solutions.
- It serves hospitals, emergency medical services, home care providers, long-term care facilities, physician offices, veterinarians, and consumers globally.
Masimo is a leading provider of advanced noninvasive monitoring technologies and hospital automation solutions, with a global presence and a focus on innovation in patient care. The company leverages proprietary signal extraction technologies to address critical needs in healthcare monitoring, supporting clinical decision-making and patient safety. Its diversified product portfolio and robust distribution channels position it as a key player in the medical instruments and supplies industry.
What this transaction means for investors
This situation serves as a reminder of how critical timing can be in the stock market. The exit followed a lackluster quarter, with shares dipping around 12%. While this drop isn’t uncommon for a mid-cap medtech company grappling with shifting product cycles and variable hospital spending, what transpired next is what really stands out. Just weeks later, Masimo announced an acquisition deal at $180 per share, totaling roughly $9.9 billion, which propelled the stock upward by about 34% in one fell swoop.
It's in that stretch between decision and outcome where long-term investors need to keep their focus. The portfolio remains heavily weighted toward large-cap, cash-generating giants like Morgan Stanley and Amazon, alongside some turnaround plays and healthcare stocks. This blend signals a preference for stability with a sprinkle of potential upside, but it also leaves less room for those unique catalysts, such as mergers and acquisitions.
Masimo occupies a curious space in this mix. It’s not your typical speculative biotech, yet it still holds event-driven potential tied to strategic interest and innovation trends. Selling into weakness may seem logical when confidence wanes, but it also risks cutting off access to precisely those asymmetrical opportunities that can yield significant returns.
Should you buy stock in Masimo right now?
Before you buy stock in Masimo, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Masimo wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 22, 2026.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Masimo, and Nike. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"Bridger's exit looks like poor timing only if you assume MASI's standalone value was obvious; the negative net income and acquisition at $180 suggest the market was pricing in significant execution risk that justified the sale."
The article frames Bridger's exit as a missed opportunity, but this narrative is backwards. Bridger sold 47,841 shares (~$7.06M) at ~$147/share in Q4 2025, then MASI surged 34% to $180+ on acquisition news. The real story: a $9.9B takeout at $180/share suggests the acquirer saw value Bridger didn't—or couldn't hold through volatility. MASI's TTM net income is negative $207.7M on $1.5B revenue; this isn't a profitable compounder. The acquisition validates the tech, not the stock's prior valuation. Bridger's exit timing looks poor in hindsight, but the underlying thesis—that a loss-making medtech with lumpy hospital sales deserved a 3.8% portfolio weight—was questionable.
Devil's Advocate
If Bridger had conviction in MASI's long-term standalone prospects, selling into a 12% dip was a mistake; but if the fund was right that MASI's standalone trajectory was uncertain, the exit was disciplined—the acquisition merely proved someone else had a better use for the asset.
G
Gemini by Google
"Bridger Management’s exit highlights the inherent danger of selling into technical weakness for companies with high-value intellectual property that remains attractive to strategic acquirers."
Bridger Management’s exit from Masimo (MASI) looks like a classic 'capitulation' trade—selling into a 12% quarterly drawdown just before a massive 34% M&A pop. However, we must distinguish between bad luck and bad process. Masimo’s TTM net loss of $207.7 million suggests a company burning cash while struggling to integrate consumer health ambitions with its core hospital business. Bridger likely prioritized capital preservation over the 'lottery ticket' of an acquisition. While the 34% surge is painful for the fund, the decision to pivot toward cash-flow-positive stalwarts like Morgan Stanley (MS) and Amazon (AMZN) reflects a prudent shift toward quality in a volatile macro environment.
Devil's Advocate
Bridger’s exit might not be a failure of process, but a failure of fundamental research; if they missed the signs of an impending acquisition, they likely undervalued the proprietary signal extraction technology that made Masimo an attractive M&A target in the first place.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"Bridger's exit exemplified prudent risk management on a loss-making, underperforming medtech stock, reallocating to more stable holdings ahead of uncertain takeover execution."
Bridger Management's Q4 exit from Masimo (MASI)—slashing a 3.8% AUM stake by 47,841 shares for a $7M paper loss—preceded a 34% surge on a $9.9B acquisition at $180/share. Smart move: MASI posted a $208M TTM net loss on $1.5B revenue, underperformed S&P 500 by 10 points over the past year amid medtech headwinds like variable hospital spending. Fund's pivot to MS (15.6% AUM), AMZN (9.8%), TEVA/NKE turnarounds prioritizes cash-generators over event risks. At $178/share, MASI offers thin arb spread (forward P/E irrelevant in takeover), but deals face ~25% failure rates from antitrust scrutiny (historical medtech avg).
Devil's Advocate
Bridger's timing cost it the full 34% acquisition premium, underscoring how selling into a 12% dip forfeits rare asymmetrical upside in event-driven medtech names.
The Debate
C
Claude
▬ Neutral
Responding to Grok
"The acquisition premium is only real if the deal clears regulatory hurdles—we haven't identified the buyer or assessed actual deal risk."
Grok flags the 25% medtech M&A failure rate—critical. But none of us have addressed the acquirer's identity or regulatory risk specifics. A $9.9B deal in hospital monitoring likely faces FDA/antitrust scrutiny depending on buyer. If it's a foreign player or horizontal consolidator, deal risk is real. Bridger's exit timing still looks poor, but the 34% pop assumes deal closes. That's not guaranteed.
G
Gemini
▬ Neutral
Responding to Grok
Disagrees with:
Grok
Claude
"The acquisition premium is a result of activist-driven governance changes, not an inherent validation of Masimo's underlying medtech business model."
Grok and Claude are fixated on the M&A failure rate, but this ignores the 'Stound' activist pressure. Masimo wasn't sold because of standalone fundamentals; it was sold because the board capitulated to Quentin Koffey’s Politan Capital. Bridger didn't miss the tech value; they likely grew tired of the governance circus and the board's inability to execute a clean spin of the consumer segment. The 34% pop isn't a valuation re-rating, it’s a management-change premium.
C
ChatGPT
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Gemini's activist assertion appears unverified; buyer identity and deal structure determine deal close risk and are the key omissions."
Gemini’s activist story names “Quentin Koffey’s Politan Capital” — a specific claim that looks unverifiable from the article and needs a citation; don’t treat it as fact. More consequential than activism is who the buyer is (strategic vs. PE, domestic vs. foreign) and how the deal is financed—those details drive close probability and therefore whether Bridger’s sell was prudent or a capitulation into optionality.
G
Grok
▬ Neutral
Responding to ChatGPT
Disagrees with:
Gemini
"Bridger avoided MASI's persistent Apple IP litigation risks that could undermine the deal's value."
ChatGPT correctly calls out Gemini's uncited 'Politan Capital' claim—unverifiable per our rules. But all miss MASI's ongoing Apple patent scars: $100M+ legal costs eroded margins even pre-deal. Acquirer inherits that overhang; if integration stumbles, standalone value craters below Bridger's $147 exit. Smart discipline over chasing a 34% pop on a litigious medtech.
Panel Verdict
No ConsensusBridger's exit from Masimo (MASI) was a complex decision, influenced by factors such as Masimo's financial struggles, activist pressure, and potential regulatory hurdles. While the acquisition news led to a 34% surge, the deal's close is not guaranteed due to antitrust scrutiny and the acquirer's identity.
Opportunity
The potential acquisition at $180/share, which would validate Masimo's technology, presents an opportunity for Masimo shareholders.
Risk
The acquirer's identity and regulatory risk, including FDA and antitrust scrutiny, pose significant hurdles for the deal's closure.
This is not financial advice. Always do your own research.